التفاصيل البيبلوغرافية
العنوان:
Data from Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer
المؤلفون:
Ben H. Park , Vered Stearns , Jane Zorzi , Zhe Zhang , Daniel J. Zabransky , Lauren E. Young , Antonio C. Wolff , Dustin A. VanDenBerg , Philip J. Stephens , Shannon Slater , Jeffrey S. Ross , Gary L. Rosner , Geoff A. Otto , Vincent A. Miller , Doron Lipson , Justin Lee , Josh Lauring , Mark R. Kennedy , Stacie C. Jeter , Christopher D. Gocke , Travis A. Clark , Sarah Croessmann , Rory L. Cochran , Roisin M. Connolly , David Chu , Jennifer Axilbund , Siraj M. Ali , Ashley Cimino-Mathews , Julia A. Beaver , Heather A. Parsons
بيانات النشر:
American Association for Cancer Research (AACR), 2023.
سنة النشر:
2023
الوصف:
Purpose: The clinical utility of next-generation sequencing (NGS) in breast cancer has not been demonstrated. We hypothesized that we could perform NGS of a new biopsy from patients with metastatic triple-negative breast cancer (TNBC) in a clinically actionable timeframe.Experimental Design: We planned to enroll 40 patients onto a prospective study, Individualized Molecular Analyses Guide Efforts (IMAGE), to evaluate the feasibility of obtaining a new biopsy of a metastatic site, perform NGS (FoundationOne), and convene a molecular tumor board to formulate treatment recommendations within 28 days. We collected blood at baseline and at time of restaging to assess cell-free circulating plasma tumor DNA (ptDNA).Results: We enrolled 26 women with metastatic TNBC who had received ≥1 line of prior chemotherapy, and 20 (77%) underwent NGS of a metastatic site biopsy. Twelve (60%) evaluable patients received treatment recommendations within 28 days of consent. The study closed after 20 patients underwent NGS, based on protocol-specified interim futility analysis. Three patients went on to receive genomically directed therapies. Twenty-four of 26 patients had genetic alterations successfully detected in ptDNA. Among 5 patients, 4 mutations found in tumor tissues were not identified in blood, and 4 mutations found in blood were not found in corresponding tumors. In 9 patients, NGS of follow-up blood samples showed 100% concordance with baseline blood samples.Conclusions: This study demonstrates challenges of performing NGS on prospective tissue biopsies in patients with metastatic TNBC within 28 days, while also highlighting the potential use of blood as a more time-efficient and less invasive method of mutational assessment. Clin Cancer Res; 23(2); 379–86. ©2016 AACR.
URL الوصول:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ccbc9a10eb6d0761509999c0ea9a4ed https://doi.org/10.1158/1078-0432.c.6526784.v1
حقوق:
OPEN
رقم الأكسشن:
edsair.doi.dedup.....5ccbc9a10eb6d0761509999c0ea9a4ed
قاعدة البيانات:
OpenAIRE
